Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral develops devices for unmet medical needs. Sepsis occurs in 1.7M Americans/year causing 250K deaths, often caused by endotoxin. Our devices measure and remove endotoxin from the bloodstream. An FDA confirmatory trial is underway. Dialco, a Spectral sub, offers SAMI, a novel instrument for renal replacement, cleared by FDA. Dialco is seeking FDA approval for DIMI a unique home dialysis enabler. These devices have large commercial potential


TSX:EDT - Post by User

Post by PezDalatoYouon Mar 24, 2022 2:06pm
209 Views
Post# 34542370

Dialysis Perspective

Dialysis Perspective'Nearly 786,000 people in the United States are living with ESKD, also known as end-stage renal disease (ESRD), with 71% on dialysis and 29% with a kidney transplant.' So doing the math, there are about 550k people on dialysis in the United States. We can't find 35 out of those 550k who are interested in trying the latest new and portable machine? I'm not sure how that is even possible unless you are literally not trying at all...
<< Previous
Bullboard Posts
Next >>